1.290USD-5.15%Mkt Cap: 3.76M USDP/E: 0.74Last update: 2026-05-26
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and in…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap3.76M USD
Enterprise Value18.67K USD
Revenue (TTM)142.00K USD
Gross Profit139.00K USD
Net Income (TTM)-2.49M USD
Revenue/Share0.0610 USD
Last Price1.290 USD
Fiscal Year EndMar 2025
MR QuarterDec 2025
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.74
P/E (Forward)—
PEG—
EV/EBITDA-0.00
EV/Revenue0.13
P/S27.31
P/B0.79
EPS (TTM)1.76
EPS (Forward)—
52W Range
1.2202% of range5.300
52W High5.300 USD
52W Low1.220 USD
Profitability
Gross Margin96.53%
Oper. Margin-10576.92%
EBITDA Margin0.00%
Profit Margin-1727.78%
ROE-23.71%
ROA-16.98%
Growth
Revenue Growth8.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.46M USD
CapEx (TTM)13.00K USD
FCF Margin-5560.48%
FCF Yield-209.84%
Net Debt-3.48M USD
Net Debt/EBITDA0.31
Balance Sheet
Debt/Equity0.09
Current Ratio2.44
Quick Ratio1.75
Book Value/Sh1.703 USD
Cash/Share1.644 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 19, 2020
Splits
Last Split1:12
Split DateMar 21, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.89M
Float2.33M
Insiders13.08%
Institutions7.81%
Short Interest
Short Ratio0.8d
Short % Float1.84%
Short % Out.1.82%
Shares Short52.79K
Short (prev mo.)91.22K
Technical
SMA 501.519 (-15.1%)
SMA 2002.139 (-39.7%)
Beta1.41
S&P 52W Chg28.31%
Avg Vol (30d)48.98K
Avg Vol (10d)49.05K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—